Andrew Paul Mazar - Chief Scientific Officer, Director at Monopar Therapeutics

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Scientific Officer, Director
Issuer Symbol
MNPR on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Andrew Paul Mazar since 09 Feb 2025

Holdings reported by Andrew Paul Mazar for Monopar Therapeutics

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 166,667 $56,700 $0.3402 31 Mar 2022 Indirect
Restricted Stock Units 88,792 $30,207 $0.3402 31 Mar 2022 Direct Common Stock
Common Stock 22,125 $7,527 $0.3402 31 Mar 2022 Direct
Stock Options 88,874 02 Feb 2022 Direct Common Stock

Transactions reported by Andrew Paul Mazar for Monopar Therapeutics

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.